Skip to main content
Glecaprevir, pibrentasvir effective in those with HCV, liver disease
4/10/2019

An integrated analysis of nine trials in the Phase II and III stages assessed glecaprevir and pibrentasvir as a treatment for chronic hepatitis C genotype 1 to 6 infections and indicated that the regimen was safe and effective in those with compensated liver disease as well as those with stage IV or stage V chronic kidney disease. Details of the analysis were published in the journal Clinical Infectious Diseases.

Full Story: